Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diabetes and dyslipidemia.

H N Ginsberg1, C Tuck

  • 1College of Physicians and Surgeons of Columbia University, New York, NY 10032, USA.

Heart Failure Monitor
|March 14, 2003
PubMed
Summary
This summary is machine-generated.

Diabetes mellitus significantly increases coronary heart disease risk, especially in women and younger adults. Diabetic dyslipidemia, characterized by abnormal lipid levels, contributes substantially to this elevated risk and requires aggressive management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

3D-printed components for quantum devices.

Scientific reports·2018
Same author

Fermentable short chain carbohydrate (FODMAP) content of common plant-based foods and processed foods suitable for vegetarian- and vegan-based eating patterns.

Journal of human nutrition and dietetics : the official journal of the British Dietetic Association·2018
Same author

Meso-scale defect evaluation of selective laser melting using spatially resolved acoustic spectroscopy.

Proceedings. Mathematical, physical, and engineering sciences·2017
Same author

Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience.

Diabetologia·2012
Same author

Diabetes and dyslipidemia.

Current diabetes reports·2003
Same author

HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia.

Nature medicine·2001
Same journal

Women, men and heart failure: a review.

Heart failure monitor·2008
Same journal

Anemia and erythropoietin in heart failure.

Heart failure monitor·2008
Same journal

The pharmacological rationale behind polypharmacy in heart failure.

Heart failure monitor·2008
Same journal

Diuretics - a panacea for acute heart failure? Different formulations, doses, and combinations.

Heart failure monitor·2008
Same journal

Congenital heart disease and heart failure.

Heart failure monitor·2008
Same journal

Neuregulin-1 and its potential role in the control of cardiac function.

Heart failure monitor·2008
See all related articles

Area of Science:

  • Cardiology
  • Endocrinology
  • Metabolic Disorders

Background:

  • Diabetes mellitus (DM), particularly type-2 DM, is linked to a 3-4 fold increased risk of coronary heart disease (CHD).
  • This elevated risk is more pronounced in younger individuals and women, who lose their typical cardioprotection.
  • DM patients face higher in-hospital mortality and a doubled risk of death within two years post-myocardial infarction.

Purpose of the Study:

  • To review the pathophysiology of diabetic dyslipidemia in type-2 DM.
  • To explain the contribution of dyslipidemia to the increased CHD risk in diabetic patients.
  • To discuss aggressive management strategies for diabetic dyslipidemia.

Main Methods:

  • Review of prospective cohort studies and existing literature on diabetes mellitus and coronary heart disease.

Related Experiment Videos

  • Focus on the lipid and lipoprotein abnormalities characteristic of type-2 DM.
  • Discussion of the underlying mechanisms of dyslipidemia in type-2 DM.

    • Main Results:

    • Type-2 DM is associated with abnormal plasma lipid profiles, including elevated very low-density lipoprotein triglycerides.
    • Reduced high-density lipoprotein cholesterol and the presence of small, dense low-density lipoproteins are key features.
    • These dyslipidemic patterns significantly contribute to the excess CHD risk observed in diabetic individuals.

    Conclusions:

    • Diabetic dyslipidemia is a major contributor to the heightened cardiovascular risk in patients with type-2 DM.
    • Aggressive management including diet, weight loss, and lipid-altering medications is crucial.
    • Combination therapies, such as statins and fibrates, can effectively normalize lipid levels.